A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
ImmunityBio, Inc.
Beijing Boren Hospital
VectivBio AG
Australasian Leukaemia and Lymphoma Group
Fondazione Italiana Linfomi - ETS
National Cancer Institute (NCI)
Zhujiang Hospital
University of Nebraska
Oncternal Therapeutics, Inc
UNC Lineberger Comprehensive Cancer Center
SecuraBio
University of California, San Francisco
Calithera Biosciences, Inc
Presage Biosciences
Medigene AG
Abramson Cancer Center at Penn Medicine
SecuraBio
CTI BioPharma
Bellicum Pharmaceuticals
National Cancer Institute (NCI)
Louisiana State University Health Sciences Center Shreveport
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Fuda Cancer Hospital, Guangzhou
CTI BioPharma
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
University of Maryland, Baltimore
University of California, San Francisco
University of Texas Southwestern Medical Center
University of Southern California
Ann & Robert H Lurie Children's Hospital of Chicago
NantBioScience, Inc.
University of California, San Diego
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
Kahr Medical
M.D. Anderson Cancer Center
Dartmouth-Hitchcock Medical Center
Yale University
RedHill Biopharma Limited
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
The Methodist Hospital Research Institute
National Institutes of Health Clinical Center (CC)
Western Regional Medical Center
Baylor Research Institute
Johns Hopkins University